Dr. Jonathan Trent on Engineered T- cell Therapy in Sarcoma


Jonathan C. Trent, MD, PhD, professor of medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses T-cell therapies in sarcoma.

Many types of sarcomas have translocations and point mutations that lead to novel antigens that can be specifically recognized by an engineered T cell, says Trent.

There are also several types of sarcoma, such as synovial sarcoma and liposarcoma that express testicular antigens—such as NY-ESO-1—that are not expressed in any other cell in the human body. These neoantigens can be targets of modified T-cells, such as the T-cells that are now being engineered by a number of different companies to bind to and kill NY-ESO-1 in synovial sarcoma and liposarcoma cells.

Clinical trials are available investigating these agents.

Related Videos
Peter Schmid, MD, PhD
Seema A. Khan, MD
Roisin E. O'Cearbhaill, MD
Stephen J. Freedland, MD
Tapan M. Kadia, MD,
Sara M. Tolaney, MD, MPH
Javier Cortés, MD, PhD,
Stephanie L. Graff, MD
Senthil Damodaran, MD, PhD
Eytan M. Stein, MD